1 / 5

Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data -

Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data -. Heribert Knechten, MD PZB Aachen, Germany. T = 5. Abstract No.: TUPDB202. Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data -. N = 51

jude
Download Presentation

Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data - Heribert Knechten, MD PZB Aachen, Germany T = 5

  2. Abstract No.:TUPDB202 Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data - N = 51 HIV-1 subtype B 86% Phenotype + Genotype N = 32 Phenotype only N = 6 Genotype only N = 13 Median Active Drug Score (ADS*) 3 Results Week 24 N = 42 Median Viral load < 40 copies/mL Median CD4 count 565 cells/µl (BL 415 cells/µl) Therapy success N = 32 (76.2%) * including MVC

  3. Positive predictive values for geno2pheno and TROFILE in predicting R5-tropic viruses Positive Predictive Value: g2p (FPR 10%) 77.2% g2p (FPR 20%) 73.7% TROFILE™ 78.2% FPR: false positive rate is the probability of classifying an R5-viruses falsely as X4

  4. Virological response in groups with different active drug scores (ADS incl. Maraviroc) ADS < 3 ADS 3 - 4 ADS ≥4 median median median week week week ADS according to www.hiv-grade.de: resistant = 0; intermediate = 0.33; Limited susceptibility = 0.66; susceptible = 1; hypersusceptibility = 1.33

  5. Thanks to: Stefan Christensen, Medical Practice, Münster, Germany; Martin Hower, Städt. Klinik Dortmund, Germany; Hans Jäger, MUC Research, Munich, Germany; Wolfgang Köthemann, Medical Practice, Cologne, Germany; Anton Neuwirth, Medical Practice, Cologne, Germany; Eiko Schnaitmann, Medical Practice, Stuttgart, Germany; Stefan Scholten, Medical Practice, Cologne, Germany; Andreas Trein,  Medical Practice, Stuttgart, Germany; Eva Wolf, MUC Research, Munich, Germany;

More Related